MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation for providing reliable sequencing, genotyping, microarray, and bioinformatics services. To help scientific researchers better understand fungal biodiversity, physiology, metabolism and function, CD Genomics MicrobioSeq has launched the fungal whole-genome de novo sequencing service.

Fungi are vital to the biosphere and human health due to their important medical and economic value. Some fungi are closely related to animals, plants and other life forms by developing symbiotic relationships. Fungi also produce some secondary metabolites, such as penicillin, cyclosporine and lovastatin, which have important medicinal, agricultural or cosmetic prosperities.

Fungal genome research is a method to obtain the whole fungal genome sequence through genome sequencing and assembly, and to study its structure and function. In-depth research on these strains also allows us to better understand and utilize fungal resources to create greater value.

Traditional techniques cannot handle the large amount of data required for fungal genome-wide research because fungal genomes are typically large and complex. At present, the strategy of combined assembly of short-read and long-read sequencing can realize the advanced assembly of fungi, and some projects can be assembled to the level close to the completed map, which provides strong support for the research of fungi.

“CD Genomics utilizes both long-read and short-read sequencing technologies for fungal whole-genome de novo sequencing. Both the PacBio and Nanopore platforms are superior long-read sequencing platforms that generate reads with tens of kilobases in length for better genome reconstruction. A single molecule of DNA can be sequenced without the need for PCR amplification or chemical labeling of the sample. De novo assembly from long reads can span the low complexity and repetitive regions and create accurate assemblies. Additionally, we perform fungal whole-genome de novo sequencing on Illumina HiSeq, which is a short-read sequencing platform with high accuracy,” said Dianna, Marketing Manager of CD Genomics.

“Fungal whole genome de novo sequencing, which is used to investigate new fungal populations, allows for the reconstruction of fungal genomes, functional analyses, and evolutionary studies. This technique can shed light on the biological diversity of fungi and yeast, so broadening research into agricultural science, ecology, bioremediation, medical science, cosmetic science, bioenergy, and the biotechnology business,” she added.

Advantages of CD Genomics’s fungal whole-genome de novo sequencing:

1. The least degree of bias and longer read lengths (average > 15,000 bp, some reads >100,000 bp) generated by long-read sequencing instruments.
2. Advanced sequencing platforms: Illumina HiSeq, Nanopore MinION, and PacBio Sequel platforms.
3. Extensive experience in the industry of genomic service.
4. Professional bioinformatics analysis team.